[Controled trial of an anorectic (An 448) in the treatment, of childhood obesity]. 1976

P Canlorbe, and P Borniche, and J E Toublanc

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007228 Infant Nutrition Disorders Disorders caused by nutritional imbalance, either overnutrition or undernutrition, occurring in infants ages 1 month to 24 months. Infant Malnutrition,Malnutrition, Infant,Nutrition Disorders, Infant,Infant Overnutrition,Infantile Malnutrition,Malnutrition in Infant,Infant Nutrition Disorder,Malnutrition in Infants,Malnutrition, Infantile,Nutrition Disorder, Infant,Overnutrition, Infant
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

P Canlorbe, and P Borniche, and J E Toublanc
June 1977, La Clinica terapeutica,
P Canlorbe, and P Borniche, and J E Toublanc
June 1974, The Medical journal of Australia,
P Canlorbe, and P Borniche, and J E Toublanc
June 1966, Archives of disease in childhood,
P Canlorbe, and P Borniche, and J E Toublanc
March 1976, The Medical journal of Australia,
P Canlorbe, and P Borniche, and J E Toublanc
February 1973, Casopis lekaru ceskych,
P Canlorbe, and P Borniche, and J E Toublanc
July 1967, The British journal of clinical practice,
P Canlorbe, and P Borniche, and J E Toublanc
February 1994, Archives of family medicine,
P Canlorbe, and P Borniche, and J E Toublanc
November 1963, Clinical medicine (Northfield, Ill.),
P Canlorbe, and P Borniche, and J E Toublanc
July 1975, The Keio journal of medicine,
P Canlorbe, and P Borniche, and J E Toublanc
January 2008, Nutricion hospitalaria,
Copied contents to your clipboard!